AUTHORS
Ruida Hou, MD, PhD, Yan Jin, PhD2, Zhenhua Li, PhD3, Shilpa Narina4, Yuxuan Liu, PhD5, Ashley Gray6, Jingwen Zhu, PhD7, John D Schuetz, PhD8, Shondra M. Pruett-Miller, PhD9, Zheng Wu, PhD10, Kara L. Davis, D.O.11, Min Ni, PhD12, Jun J. Yang, PhD13
AFFILIATIONS
1 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
3 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
4 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Stanford University, Stanford, California, United States
6 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
8 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
9 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
10 The University of Texas Southwestern Medical Center, Dallas, Texas, United States
11 Stanford University, Stanford, California, United States
12 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
13 St.Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
Background: Dihydroorotate dehydrogenase (DHODH) couples de novo pyrimidine synthesis to the mitochondrial electron transport chain (ETC) and is an emerging therapeutic target in blood cancers, including T-cell acute lymphoblastic leukemia (T-ALL). However, the molecular determinants of DHODH inhibition (DHODHi) response remain incompletely defined. To this end, we performed genome-wide CRISPR screen, metabolic tracing, and proximity labeling proteomics to comprehensively characterize mechanisms underlying DHODHi cytotoxicity and drug resistant in T-ALL.
Methods: Ten T-ALL cell lines were treated with three distinct DHODH inhibitors: brequinar, BAY2402234, and farudodstat. Genome-wide CRISPR Knockout screen was performed in KOPT-K1 cell line under brequinar selection. Drug-induced changes in apoptosis, cell cycle, DNA damage, mitochondrial respiration, and pyrimidine metabolism were assessed by CellTiter-Glo, flow cytometry, Seahorse analysis, and isotope tracing. MiniTurbo proximity labeling combined quantitative proteomics was used to identify treatment-induced changes in the DHODH interactome.
Results: DHODH inhibitors showed heterogeneous activity across T-ALL cell lines representing 5 different molecular subtypes, with LC50 values spanning 1,000-fold. KOPT-K1 (TAL1 T-ALL) consistently ranked as the most sensitive cell line, whereas ALL-SIL (TLX1) and LOUCY (HOXA9) were the most resistant models across the panel. Cytotoxicity of different DHODH inhibitors was correlated with each other across cell lines.
In sensitive cell lines, DHODH inhibition rapidly induced early S-phase cell cycle arrest within 8 hrs, followed by activation of DNA replication stress and DNA damage as evidenced by increased phospho-CHK1 and γH2AX accumulation. By 16 hours, apoptosis was markedly increased and was attenuated by a pan-caspase inhibitor Q-VD-OPh, indicating caspase-dependent cell death.
Using genome-wide CRISPR screen, we next identified 34 significant sensitivity-associated genes (Log2[fold change] >1, and P < 0.001), with the top 2 genes UCK2 and SLC29A1 that are linked to pyrimidine salvage. On the other hand, mitochondrial respiratory-chain genes were strongly enriched among resistance-associated hits (NES = 2.37, P < 0.0001), especially those encoding mitochondrial Complex I proteins. Moreover, pharmacologic inhibition of pyrimidine salvage enhanced DHODHi sensitivity, whereas Complex I inhibition conferred resistance, validating the genetic findings.
Stable isotope tracing showed that brequinar suppressed de novo pyrimidine synthesis by up to 46.8 % in T-ALL (P < 0.0001). However, DHODH inhibition did not significantly increase pyrimidine salvage during the first 6 hours, suggesting that rapid compensatory upregulation of this pathway is not a prominent early response to DHODH inhibition.
Given the established link between DHODH and mitochondrial respiration, as well as our CRISPR hits implicating this pathway, we sought to define how DHODH inhibition alters mitochondrial function in T-ALL. DHODHi profoundly reduced maximal respiratory capacity within 8 hours and suppressed CoQ-linked electron transport, particularly succinate-supported oxygen consumption, which decreased by up to 73%. MiniTurbo proximity-labeling proteomics further revealed treatment-induced remodeling of the DHODH interactome, with increased association between DHODH and multiple Complex I proteins, consistent with reorganization of the DHODH–ETC interface following DHODH inhibition.
Conclusions: Our findings establish mitochondrial respiratory state as a central determinant of DHODH inhibitor response in T-ALL and provided new insights into the crosstalk between de novo pyrimidine synthesis and ETC organization. These insights provide a mechanistic foundation for developing predictive biomarkers and rational combination strategies for DHODH inhibitor-based therapy in T-ALL.
DISCLOSURES
Ruida Hou, MD, PhD: No relevant conflicts of interest to declare.